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Abstract
Traumatic brain injury (TBI) is a leading cause of death in young adults, and effective treatment strat-
egies have the potential to save many lives. TBI results in coagulopathy, endothelial dysfunction,
inflammation, cell death, and impaired epigenetic homeostasis, ultimately leading to morbidity and/
or mortality. Commonly used resuscitation fluids such as crystalloids or colloids have several disad-
vantages and might even be harmful when administered in large quantities. There is a need for next-
generation treatment strategies (especially in the prehospital setting) that minimize cellular damage,
improve survival, and enhance neurological recovery. Pharmacologic treatment with histone deace-
tylase inhibitors, such as valproic acid, has shown promising results in animal studies of TBI and may
therefore be an excellent example of next-generation therapy. This review briefly describes tradi-
tional resuscitation strategies for TBI combined with hemorrhagic shock and describes preclinical
studies on valproic acid as a new pharmacologic agent in the treatment of TBI. It finally discusses limi-
tations and future directions on the use of histone deacetylase inhibitors for the treatment of TBI.
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1 | INTRODUCTION
Despite optimization of prehospital and intrahospital treatment strat-
egies, traumatic brain injury (TBI) remains a leading cause of morbidity
and mortality in young adults (Faul, Wald, & Coronado, 2010; Centers
for Disease Control and Prevention, 2011). TBI is often paralleled by
hemorrhagic shock (HS), and this combination is especially lethal, with
studies showing that HS can significantly worsen TBI-associated mor-
bidity and mortality (Wald, Shackford, & Fenwick, 1993; McMahon,
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Yates, Campbell, Hollis, Woodford, 1999). TBI and HS result in second-
ary conditions such as inflammation, endothelial dysfunction, coagulop-
athy, hypoxia, and cerebral edema. Such secondary insults are highly
linked, and include cross-talk between endothelial and coagulation
pathways as key mediators. The primary insult to the brain occurs in
the prehospital setting, involves irreversible destruction of neuronal tis-
sue and cannot be treated. Hence, treatment strategies necessarily
focus on prevention of secondary brain injury by maintaining adequate
cerebral oxygenation and perfusion (Badjatia 2008). Fluid resuscitation
has historically been the mainstay in treating traumatic injuries. It plays
a critical role in restoring and maintaining systemic and cerebral circula-
tion in TBI patients (Myburgh et al., 2007). An ideal resuscitation fluid
would therefore minimize cerebral edema, as well as attenuate neuro-
nal damage, inflammation, and coagulopathy. However, current resusci-
tation strategies have failed to prevent this secondary brain injury. For
this reason, recent advances in trauma research have focused on next-
generation fluids and pharmacologic agents that may attenuate sec-
ondary brain injury. The aim of this review is to describe traditional
resuscitation strategies for TBI combined with HS, and discuss the
novel use of valproic acid (VPA) as a new pharmacologic agent in the
treatment of TBI.
2 | CONVENTIONAL RESUSCITATION
TREATMENTS
TBI is often associated with hypovolemia, HS, and coagulopathy. In
addition, microvascular injury may alter the permeability of the blood-
brain barrier (BBB), resulting in intravascular fluid leakage and cerebral
edema. The ideal resuscitation strategy should aim to not only replace
lost blood but also minimize secondary brain injury. Accordingly, current
strategies focus on hemodynamic stabilization, maintaining systemic cir-
culation, and optimizing cerebral perfusion (Hammell & Henning, 2009;
Myburgh et al., 2007). However, there is considerable debate about the
most effective methods for treating blood loss associated with TBI.
2.1 | Fluid resuscitation
Prompt fluid resuscitation is the first-line therapy to restore the lost intra-
vascular volume. As blood products are often unavailable at the scene of
the injury, prehospital management is usually limited to infusion using
crystalloids or colloids. Isotonic crystalloids are typically preferred over
colloids (Myburgh et al., 2007; Perel & Roberts, 2012) and have served
as the standard resuscitation fluid for some time. Yet, traditional resusci-
tation fluids such as crystalloids have no inherent prosurvival properties
(Santry & Alam, 2010), and in severely bleeding patients, aggressive crys-
talloid resuscitation does not result in any survival benefit (Bickell et al.,
1994; Kwan, Bunn, & Roberts, 2003). Moreover, several clinical studies
have identified shortcomings of fluid resuscitation, such as hemodilution,
hemostatic derangements, brain edema, and inflammation (Grande,
Asgeirsson, & Nordstrom, 1997; Peiniger et al., 2011). Such aggressive
administration may even worsen outcomes by further exaggerating the
cellular damage suffered during shock (Santry & Alam, 2010). Preclinical
studies showed that ongoing hemorrhage and coagulopathy are
frequently not corrected by current resuscitation protocols using crystal-
loids and packed red blood cells (PRBCs) (Selby et al., 1996). In addition,
massive fluid resuscitation itself may even result in coagulopathy and
hemodilution (Selby et al., 1996; Sondeen, Coppes, & Holcomb, 2013).
Compared with other resuscitation fluids such as fresh frozen plasma
(FFP) or colloids, normal saline resuscitation is furthermore associated
with increased brain swelling (Jin, DeMoya, et al. (2012; Imam et. al.
2015); metabolic derangements (Hwabejire, Imam, et al., 2013b); ele-
vated circulating markers of injury (Sillesen, Jin, et al., 2013); and
increased activation of the endothelial, coagulation, and anticoagulation
systems (Dekker, 2014c; Sillesen et al., 2014).
These findings suggest that traditional fluid resuscitation with crystal-
loids is mostly supportive, and does not address the specific cellular dys-
function caused by shock and injury. Because of the increased awareness
of the negative effects of massive transfusions, trauma care now favors
“damage control resuscitation” consisting of minimal use of crystalloids,
early hemorrhage control, and early administration of blood products
(PRBC, FFP, and platelets in an appropriate ratio) (Kwan et al., 2003).
2.2 | Blood product resuscitation
Commonly used blood products are PRBC, FFP, platelets, and fibrino-
gen. There is limited evidence concerning the use of PRBC in the set-
ting of isolated TBI. The combination of TBI and HS likely mandates
PRBC transfusion, with clinical data suggesting a survival benefit when
FFP:PRBC ratios are maintained above 1:2 (Peiniger et al., 2011). The
benefits of FFP on the control of acute traumatic bleeding and coa-
gulopathy are furthermore demonstrated in multiple clinical studies
(Borgman et al., 2007; Duchesne et al., 2008; Maegele et al., 2008; Sca-
lea et al., 2008; Wafaisade et al., 2010; Zehtabchi & Nishijima, 2009). In
the setting of TBI, however, clinical data are conflicting. Some studies
have indicated adverse outcomes associated with FFP administration
(Anglin et al., 2013; Etemadrezaie et al., 2007), while others have identi-
fied outcome benefits (Peiniger et al., 2011). Preclinical studies demon-
strated that early administration of FFP also appears to alter the clinical
course following TBI by attenuating the degree of neurologic impair-
ment, improving the rate of recovery, and preserving cognitive func-
tions (Halaweish, 2015a). These effects of blood products can even be
detected at the level of gene transcription (Sillesen, Bambakidis, Dek-
ker, Li, & Alam, 2017), affecting the expression of genes involved in
metabolism, platelet signaling, and inflammation. These data suggest
that the therapeutic benefits of plasma resuscitation might be more
extensive than solely through hemodynamic stabilization.
However, FFP transfusion is not without risk (Nascimento et al.,
2010; Rossaint et al., 2016). Such risks include transfusion-associated
acute lung injury and circulatory overload, allergic reactions, and trans-
mission of infectious diseases (Nascimento et al., 2010). Moreover, the
use of FFP and other blood products is challenging in prehospital settings
or in underdeveloped areas because of logistical issues such as limited
availability, requirement for refrigeration, short life after thawing, and the
need for immediately available universal donor plasma. These challenges
of FFP resuscitation have fueled the initiative to develop next-generation
blood products that are low volume and shelf stable.
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2.3 | Future directions of blood products
and antifibrinolytics in traumatic bleeding
Lyophilized plasma, a freeze-dried plasma product developed in the
1930s, may solve the shortcomings of FFP resuscitation. It is logistically
superior to FFP, as it can be stored as a powder for as long as 30 years,
and subsequently reconstituted and administered within minutes fol-
lowing rehydration with water (Fu & Myhre, 1977). Additionally, lyoph-
ilized plasma retains its factor function much better than FFP, and can
be stored in ambient temperatures for extended periods of time.
Freeze-dried plasma has been shown to be as effective as FFP in large
animal models of TBI and hemorrhage (Imam et al., 2013a; Halaweish
et al., 2016). Freeze-dried plasma is approved for clinical use in Europe
and has been used by NATO forces for many years with good results
(Alam & Velmahos, 2011; Pusateri et al., 2016). However, it is currently
not approved by the Food and Drug Administration (FDA) for use in
the United States. In the coming years, there is an urgent need for pro-
spective investigations of blood products such as lyophilized plasma
and fibrinogen, and antifibrinolytic drugs such as tranexamic acid (TXA).
There is currently a paucity of data concerning the use of TXA in TBI.
A recent Cochrane review concluded that TXA may reduce mortality,
although the quality of the evidence is low and uncertainties remain
(Ker, Roberts, Shakur, & Coats, 2015). Furthermore, studies have sug-
gested a reduction in the incidence of intracranial hemorrhage follow-
ing TBI associated with administration of TXA (Zehtabchi, Abdel Baki,
Falzon, & Nishijima, 2014). Future randomized controlled trials should
report on the clinical outcomes of treatment with TXA and fibrinogen
to address some of the key unanswered questions in trauma-induced
coagulopathy (Wong, Curry, & Stanworth, 2016).
3 | NOVEL RESUSCITATION
TECHNIQUES—EPIGENETIC
MODULATION USING VPA
At present, there are no proven pharmacologic treatment options for
TBI. However, the search for such therapeutic treatment of TBI has
received considerable attention in recent years (Fukudome et al., 2012;
Ichiyama et al., 2000). A therapeutic strategy for modulating the cellular
response to injury may be at the level of the epigenome. One class of
promising drugs that affect the epigenome is histone deacetylase inhib-
itors (HDACIs). In pathologic conditions, such as TBI and HS, there is a
decrease in histone acetylation, which limits gene transcription and
impairs cellular homeostasis. However, agents such as VPA have been
shown to act as HDACIs, thus altering gene transcription and thereby
inducing a “prosurvival phenotype.” The precise mechanisms underlying
these protective effects are an active area of current research.
3.1 | TBI creates a genomic storm
The genomic response to injury is an important area of current
research. Recent studies have revealed that traumatic injuries result in
epigenetic changes via DNA methylation, phosphorylation, and acetyla-
tion (Wong & Langley, 2016). The so-called “genomic storm” following
injury occurs on an epigenetic level and modulates numerous cellular
functions, protein expression, and pathways. These processes are con-
sidered “epigenetics,” meaning that they affect the gene expression
and resultant phenotype of the cell but do not alter the genome itself
(Bernstein, Meissner, & Lander, 2007; Goldberg, Allis, & Bernstein,
2007). Alam et al. showed that during hemorrhage and resuscitation, at
least 7% of the genes and downstream pathways are differentially
expressed (Alam, Stegalkina, Rhee, & Koustova, 2002). Xiao et al.
(2011) previously showed that after traumatic injury, expression of
over 80% of the leukocyte transcriptome is altered. These changes
occur rapidly after trauma and exhibit a long-lasting effect for months
after the injury (Lipponen, Paananen, Puhakka, & Pitkänen, 2016; Xiao,
2011). Modulating these epigenetic changes may thus be an important
goal of therapy in patients with TBI.
3.2 | Acetylation status regulates gene expression
and protein functions
Briefly, the human genome is organized into chromatin, a highly con-
served complex of DNA and histone proteins. DNA transcription, and
hence gene expression, is regulated by the acetylation and deacetyla-
tion of these histones. Histone deacetylases are enzymes that remove
the acetyl group from the histone, making the DNA-histone structure
more compact and therefore limiting transcription. In contrast, histone
acetyltransferases weaken DNA-histone attraction, thereby unfolding
the complex and making DNA more available for transcription (Del-
cuve, Khan, & Davie, 2012). A homeostatic balance between histone
deacetylases and histone acetyltransferases typically exists in cells.
However, dysregulation of acetylation homeostasis has been suggested
to play a key role in the pathogenesis of cancers and neurodegenera-
tive diseases. Moreover, as noted above, dysregulation of acetylation
homeostasis has also been implicated as an important pathologic mech-
anism in the body’s response to traumatic injuries. Thus, pharmacologic
agents that can alter histone acetylation may be promising new thera-
peutic strategies for trauma, as they can rapidly and reversely modify
the transcription of desirable genes.
Although histones were considered the main target of HDACIs,
we now know that nonhistone proteins involved in key cellular func-
tions such as the cell cycle, stress response, cytoskeleton dynamics, sig-
naling, repair/healing/remodeling, communication, and proliferation are
equally involved (Glozak, Sengupta, Zhang, & Seto, 2005). At least 50
such nonhistone proteins have been well characterized (Kim & Bae,
2011), but this list is rapidly growing. In one study, 3,600 acetylation
sites (in 1,750 human proteins) were identified, which regulated nearly
all nuclear and many key cytoplasmic processes (Choudhary, 2009).
This makes acetylation a regulatory mechanism that is as prevalent and
important as phosphorylation (Kouzarides, 2000; Norris, Lee, & Yao,
2009). Acetylation of nonhistone proteins is actually even more impor-
tant than histones in the setting of severe shock and/or TBI. While it
takes some time to produce phenotype changes through modulation of
gene transcription, direct (nontranscriptional) acetylation of regulatory
proteins is extremely fast and thus more relevant for rapidly lethal con-
ditions such as shock or TBI. In short, there are many features that
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make acetylation an attractive therapeutic target: It is rapid, completely
reversible, and can be altered by drugs that are already in clinical use.
3.3 | VPA restores normal cellular acetylation
A growing body of literature suggests that VPA may alter gene expres-
sion and protein functions following TBI (Bambakidis et al., 2016; Dek-
ker, 2014b; Halaweish et al., 2015b). VPA has been in clinical use as a
mood-stabilizing and antiepileptic drug since the 1970s. In high doses,
however, VPA acts as a HDACI. High-dose VPA has been shown to
improve survival in otherwise lethal models of HS, polytrauma (Alam
et al., 2009, 2011), sepsis, and combined TBI with HS (Halaweish et al.,
2015b,c; Jepsen et al., 2014; Jin, Duggan, et al., 2012a). Yet, the pre-
cise protective mechanisms of VPA have not been well defined. A con-
ceptual model for the main protective effects of VPA is as follows: TBI
and HS result in decreased acetylation of histones and nonhistone pro-
teins, which impairs normal gene expression and alters many homeo-
static pathways, leading to cell death. In contrast, VPA acts as an
HDACI, which restores normal acetylation homeostasis and restores
normal cellular functions, ultimately leading to a prosurvival phenotype.
HDACIs, such as VPA, are a promising therapeutic approach as they
are already FDA approved for clinical use for a variety of other ill-
nesses. Importantly, VPA is effective as treatment for HS even when
administered in a single bolus in the absence of fluid resuscitation or
blood transfusion (Alam et al., 2009). Thus, VPA treatment is very
appealing as it can be rapidly administered in the prehospital setting or
battlefield environment. Table 1 summarizes the key benefits of phar-
macologic treatment with VPA in the setting of central nervous system
injury.
3.4 | VPA alters cell survival and cell death pathways
One of the first studies that investigated the effects of hemorrhage
and resuscitation on histone acetylation demonstrated that crystalloid
resuscitation results in a predominantly deacetylation profile in animal
models, and that treatment with HDACIs was able to reverse it (Lin
et al., 2006). Our research group sought to better understand this
effect of HDACI treatment at the level of gene expression. Using a por-
cine model of TBI1HS, we performed a high-throughput analysis of
cerebral gene profiling following resuscitation with either hextend or
hextend1VPA. We hypothesized that treatment with VPA would sig-
nificantly alter the early transcription of genes in pathways related to
cell survival, which may explain its previously observed neuroprotective
effects such as reduced brain lesion size and swelling. We found that
1,668 probe sets mapping to 370 known genes were differentially
expressed between hextend versus hextend1VPA groups. These genes
TABLE 1 Key effects of valproic acid treatment following central nervous system injury, with selected studies
Effect Model Reference
Increased cell survival, and decreased
apoptosis and necrosis
TBI animal model Dekker et al., 2014b
Spinal cord injury animal model Abdanipour et al., 2012
Hypoxia-induced neuronal apoptosis
in vitro model
Jin et al., 2014; Li et al., 2008
Decreased brain lesion size TBI animal model Halaweish et al., 2015b; Imam et al., 2013b; Jepsen
et al., 2014; Jin et al., 2012a; Tai et al., 2014; Yu
et al., 2013
Improved survival, faster recovery,
improved cognitive function
TBI animal model Dash et al., 2010; Halaweish et al., 2015b; Tai et al.,
2014; Yu et al., 2013
Spinal cord injury animal model Abdanipour et al., 2012; Darvishi et al., 2014
Reduced inflammation TBI animal model Bambakidis et al., 2016; Jin et al., 2012a; Nikolian
et al., 2016b; Tai et al., 2014
Glioma cell in vitro model Ichiyama et al., 2000
Spinal cord injury animal model Abdanipour et al., 2012; Darvishi et al., 2014
Restoration of BBB function TBI animal model Nikolian et al., 2016; Yu et al., 2013
Focal cerebral ischemia animal model Wang et al., 2011
Spinal cord injury animal model Lee et al., 2012
Attenuated platelet dysfunction TBI animal model Bambakidis et al., 2016; Dekker et al., 2014a;
Sillesen, Johansson, et al., 2013
Decreased metabolism and attenuated
mitochondrial dysfunction
TBI animal model Dekker et al., 2014b; Hwabejire, Jin, et al., 2013b
Modulation of cell signaling TBI animal model Dekker et al., 2014b; Nikolian et al., 2016b
BBB5blood-brain barrier; TBI5 traumatic brain injury.
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were mapped to, among others, pathways related to cell death, apopto-
sis, and necrosis (Dekker, 2014b). These findings support our hypothe-
sis that VPA alters important genes and pathways that could improve
survival.
3.5 | VPA reduces inflammation and BBB dysfunction
As described previously, secondary brain injury includes an acute
inflammatory response with BBB disruption, activation of immune cells,
and cerebral edema. The anti-inflammatory properties of VPA treat-
ment have been described previously in models of sepsis, hemorrhage,
and TBI (Jin, Duggan, et al., 2012; Liu et al., 2014; Shang et al., 2010).
In addition, Bambakidis et al. (2016) showed that VPA modulates genes
related to inflammation, cell signaling, cell adhesion, and endothelial
growth. Dash et al. (2010) furthermore showed that VPA treatment
significantly decreased Evans Blue dye extravasation in a TBI rat model,
indicating that VPA might restore BBB function following trauma. Pro-
tective effects of VPA on BBB function were also demonstrated by
Wang Leng, Tsai, Leeds, & Chuang, 2011 and Lee et al., who found a
VPA-induced reduction of matrix metalloproteinase-9, a protease that
disrupts BBB function (Lee et al., 2012; Wang, et al., 2011). This was
furthermore associated with decreased degradation of tight junction
and basement membrane–associated proteins, such as zona occludin-1
(ZO-1), and claudin-5 (Lee et al., 2012). This is in line with data from
Nikolian and Dekker et al, 2016., who found that VPA significantly
increases expression of ZO-1, laminin, and claudin-5. Expression of glu-
cose transporter 1, a marker of barrier-type endothelial cells, was also
increased in the VPA treatment group. Moreover, in vitro monolayers
treated with VPA significantly decreased permeability relative to anoxic
controls (Nikolian and Bruhn et al, 2016). Taken together, these results
suggest that protective mechanisms of VPA may involve decreasing
inflammation and correcting BBB dysfunction.
3.6 | VPA attenuates platelet dysfunction
Coagulopathy plays a major role in the mortality of patients with TBI
and HS. A particularly important mechanism of TBI-related coagulop-
athy is platelet dysfunction. For example, TBI and HS induce a combi-
nation of platelet activation but decreased function compared with
general trauma patients (no TBI) (Kutcher et al., 2012). The precise
mechanisms of this platelet dysfunction remain unclear, but it may be
mediated by the so-called “exhausted platelet syndrome.” This syn-
drome involves initial platelet hyperactivation with subsequent deple-
tion of intracellular mediators, ultimately resulting in platelet
hypofunction (Pareti, Capitanio, Mannucci, Ponticelli, & Mannucci,
1980). Sillesen et al. showed that VPA may improve platelet function
after TBI and HS, but the precise mechanisms remain unknown (Sille-
sen, Johansson, et al., 2013). One of VPA’s protective mechanisms
might be its effect on coagulopathy by preventing platelet hyperactiva-
tion, which would thereby preserve long-term platelet function. Dekker
et al. (2014a) demonstrated that the addition of VPA to FFP resuscita-
tion results in preservation of platelet activation 8hr after the TBI,
compared with FFP alone. This was reflected in both circulatory as well
as cerebral-level platelet activation. However, it remains unclear
whether this was a direct effect of VPA on platelets, or the establish-
ment of an overall prosurvival phenotype in animals treated with VPA.
Bambakidis et al. (2017) recently conducted ex vivo experiments to
test the direct effect of VPA on platelet function and coagulation.
Results showed that VPA attenuates platelet activation and improves
clot dynamics (strength and rate of formation) in blood from animals
with TBI and HS. Importantly, VPA did not appear to alter platelet or
coagulation function in blood from healthy controls.
3.7 | VPA improves neurological recovery
While recent studies demonstrated that VPA treatment reduces brain
lesion size and attenuates damage to tissues, cells, and proteins, under-
standing longer-term functional outcomes remains an important hurdle
to clinical translatability. Halaweish et al. (2015b) recently conducted a
30-day survival model of TBI1HS. Compared with normal saline resus-
citation, VPA resuscitation (150mg/kg) resulted in significantly
decreased neurological impairment, significantly faster rate of neuro-
logic recovery, and smaller brain lesion size. Moreover, although NS-
and VPA-treated animals reached similar final cognitive function scores,
the VPA group reached cognitive normalization significantly faster than
the NS controls. In addition, small animal studies showed improved
spatial memory (Dash et al., 2010) and functional recovery (Dash et al.,
2010; Tai et al., 2014; Yu et al., 2013) when VPA was added to the
treatment protocol. In animal models of spinal cord trauma, VPA treat-
ment was associated with reduced secondary damage, improved loco-
motor scores (Abdanipour, Schluesener, & Tiraihi, 2012; Darvishi,
Tiraihi, Mesbah-Namin, Delshad, & Taheri, 2014), and more rapid
recovery (Abdanipour et al., 2012) (Table 1).
4 | FUTURE DIRECTIONS
4.1 | VPA treatment shows a promising translation
to human patients
One of the challenges with new treatment strategies is the translation
of outcomes from animal models to patients in the clinical setting. Ani-
mal models are imperfect, and there are several differences between
porcine and human species in both physiology and genome. For exam-
ple, the porcine physiology is hypercoagulable relative to the human
coagulation system. One of the main limitations of research in tradi-
tional and pharmacological resuscitation is the lack of human studies.
Importantly, Sillesen et al. (2016) demonstrated that histone deacety-
lase gene expression patterns are also associated with outcomes in
actual trauma patients. Furthermore, our laboratory is currently con-
ducting a U.S. FDA-approved phase 1, double-blind, placebo-controlled
trial to evaluate the safety and tolerability of VPA in healthy volunteers
and trauma patients. The first results of this study showed that VPA
caused differential expression of a total of 173 proteins. Gene enrich-
ment analysis from these human subjects at 4 hr post infusion showed
an upregulation of pathways related to cell death, apoptosis, necrosis,
and abnormal morphology of cells and neurons. Eight hours post
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infusion, steroid metabolism, lipid synthesis, and vitamin metabolism
were also upregulated (Georgoff et al., 2016). In part 2 of the ongoing
phase 1 trial, the effects of VPA in trauma patients with HS will be
studied (ClinicalTrials.gov identifier NCT01951560). Phase 2 and 3 tri-
als have already been approved for funding and will commence in the
next few years.
4.2 | VPA dosing needs further refinement
Most experiments described in this review used a dose of 300mg/kg,
which is 6 times higher than the dose used in humans for the treatment
of seizures. While these high doses improve outcomes in animal mod-
els, they may be associated with side effects in human patients. For
example, several investigators have shown that 300-mg/kg and 400-
mg/kg doses of VPA may be toxic, with respiratory and cardiac arrest
occurring shortly after infusion (Burns, Baer, Darlington, Dubick, &
Wade, 2012). Acute VPA overdose results in hypotension, respiratory
depression, thrombocytopenia, and metabolic disorders (Manoguerra
et al., 2008). In addition, chronic VPA use (>4 weeks) has been associ-
ated with thrombocytopenia, platelet dysfunction (Davidson et al.,
2011; Gesundheit, Kirby, Lau, Koren, & Abdelhaleem, 2002; Gidal
et al., 1994; Kis et al., 1999; Manoguerra et al., 2008), and acquired
von Willebrand disease (Serdaroglu, Tutuncuoglu, Kavakli, & Tekgul,
2002; Verrotti et al., 1999). A dose as low as 60mg/kg a day has been
found to be biologically active in cancer studies, which led to our
hypothesis that lower doses might also be beneficial for trauma patients.
As detailed above, our recent test of lower-dose VPA (150mg/kg) in a
TBI1HS survival model showed promising results in terms of neurologic
recovery, cognitive outcomes, and lesion size (Halaweish et al., 2015b).
A low-dose VPA strategy was further supported by the first results of
our phase 1 trial demonstrating that VPA is biologically effective in
healthy humans when given at a dose of 120mg/kg.
4.3 | There are potential problems
with pan-HDACI treatment
VPA is cheap, well tested in multiple animal models, and approved
worldwide by regulatory agencies. However, it has been shown to
affect several different types of histones. Briefly, there are five differ-
ent histone deacetylase classes: Class I, IIa, IIb, III, and IV. Within these
classes, there are 18 different histone deacetylase isoforms (HDAC 1–
11 and SIRT 1–7). All isoforms have very different physiological func-
tions, cellular locations, and organ distributions (Halaweish et al.,
2015c). As VPA is a nonspecific pan-inhibitor, it may create significant
potential for toxicity and side effects. An important area of current
research is the development of isoform-specific HDACIs that are both
more potent and also target specific organs. Our research group is cur-
rently comparing isoform-specific HDACIs and pan-HDACIs, and inves-
tigating the synergistic effects between various HDACIs and other
cytoprotective strategies.
In particular, the use of HDAC6 inhibition has been shown to be
effective in models of sepsis (Li et al., 2015). Previous agents used in
such studies have demonstrated poor brain bioavailability and, as such,
have had limited application in the setting of TBI. Recent studies evalu-
ating the use of agents that may provide a higher brain bioavailability
(ACY-183, Acetylon Pharmaceuticals) have shown promise, with pre-
clinical and in vitro data demonstrating neuroprotective properties that
are superior to nonselective inhibitors such as VPA (Nikolian and Bruhn
et al, 2016).
5 | CONCLUSION
TBI results in coagulopathy, endothelial dysfunction, inflammation, cell
death, and impaired epigenetic homeostasis, ultimately leading to
severe injury or death. Traditional resuscitation fluids such as crystal-
loids and colloids are unable to reverse these imbalances, and might
even be harmful when administered in large quantities. There is a need
to develop next-generation resuscitation strategies that can minimize
cellular damage, improve survival, and be administered in the prehospi-
tal setting. A next-generation resuscitation protocol should involve a
combination of fluid resuscitation, blood products, and powerful phar-
macologic agents. HDACIs, such as VPA, have shown promising results
after injury and are therefore excellent examples of these next-
generation therapies. However, there is need for further refinement,
such as isoform-specific treatment, and further safety and efficacy test-
ing in human patients.
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